Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted restricted stock unit (RSU) awards to three new non-executive employees. The awards, totaling 3,875 shares of common stock, were issued under the company's 2024 Inducement Plan on August 1, 2025.
The RSUs will vest over four equal annual installments, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new hires who were not previously Praxis employees.
Praxis Precision Medicines (NASDAQ:PRAX), un'azienda biofarmaceutica in fase clinica focalizzata sui disturbi del sistema nervoso centrale, ha assegnato unità azionarie vincolate (RSU) a tre nuovi dipendenti non dirigenti. Le assegnazioni, per un totale di 3.875 azioni ordinarie, sono state emesse nell'ambito del Piano di Incentivi 2024 dell'azienda il 1° agosto 2025.
Le RSU matureranno in quattro rate annuali uguali, subordinate alla continuità lavorativa. Questi riconoscimenti sono stati effettuati in conformità alla Regola Nasdaq 5635(c)(4) come premi di incentivo per nuove assunzioni che non erano precedentemente dipendenti di Praxis.
Praxis Precision Medicines (NASDAQ:PRAX), una empresa biofarmacéutica en etapa clínica enfocada en trastornos del sistema nervioso central, ha otorgado unidades de acciones restringidas (RSU) a tres nuevos empleados no ejecutivos. Las concesiones, que suman 3,875 acciones ordinarias, se emitieron bajo el Plan de Inducción 2024 de la compañía el 1 de agosto de 2025.
Las RSU se consolidarán en cuatro cuotas anuales iguales, condicionadas a la continuidad del empleo. Estas concesiones se hicieron conforme a la Regla de Listado Nasdaq 5635(c)(4) como premios de inducción para nuevas contrataciones que no eran empleados previos de Praxis.
Praxis Precision Medicines (NASDAQ:PRAX)는 중추신경계 질환에 중점을 둔 임상 단계의 바이오제약 회사로서, 세 명의 신규 비임원 직원에게 제한 주식 단위(RSU)를 부여했습니다. 총 3,875주의 보통주가 2025년 8월 1일 회사의 2024년 유인 계획에 따라 발행되었습니다.
RSU는 4년간 매년 동일한 비율로 베스팅되며, 계속 고용 상태인 경우에 한합니다. 이 부여는 이전에 Praxis 직원이 아니었던 신규 채용자에 대한 유인 보상으로서 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Praxis Precision Medicines (NASDAQ:PRAX), une société biopharmaceutique en phase clinique spécialisée dans les troubles du système nerveux central, a attribué des unités d'actions restreintes (RSU) à trois nouveaux employés non cadres. Les attributions, totalisant 3 875 actions ordinaires, ont été émises dans le cadre du Plan d'Incitation 2024 de la société le 1er août 2025.
Les RSU seront acquises par quatre versements annuels égaux, sous réserve de la poursuite de l'emploi. Ces attributions ont été effectuées conformément à la règle de cotation Nasdaq 5635(c)(4) en tant que récompenses d'incitation pour les nouvelles recrues qui n'étaient pas auparavant employées par Praxis.
Praxis Precision Medicines (NASDAQ:PRAX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Erkrankungen des zentralen Nervensystems, hat drei neue nicht-exekutive Mitarbeiter mit Restricted Stock Units (RSUs) ausgezeichnet. Die Zuteilungen umfassen insgesamt 3.875 Stammaktien und wurden am 1. August 2025 im Rahmen des Inducement-Plans 2024 des Unternehmens gewährt.
Die RSUs werden in vier gleichen jährlichen Raten anteilig übertragen, abhängig von fortgesetzter Beschäftigung. Diese Zuteilungen erfolgten gemäß der Nasdaq-Listenregel 5635(c)(4) als Anreizprämien für neue Mitarbeiter, die zuvor keine Praxis-Angestellten waren.
- None.
- None.
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on August 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,875 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Contacts: Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
What type of stock awards did Praxis Precision Medicines (PRAX) grant to new employees?
How will the RSU awards vest for new Praxis (PRAX) employees?
Why did Praxis (PRAX) issue these stock awards?
What is Praxis Precision Medicines' (PRAX) business focus?
